



Oxytrol® (oxybutynin) – Updated indication

- On October 24, 2017, the [FDA approved](#) an update to the *Indications* section of the [Oxytrol \(oxybutynin\)](#) transdermal system drug label, for the treatment of overactive bladder in men with symptoms of urge urinary incontinence, urgency, and frequency.
 - This updated indication limits the use of Oxytrol to men only.
 - Previously, Oxytrol was indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.
- Oxybutynin transdermal system is also available over-the-counter as [Oxytrol® for Women](#), to treat overactive bladder in women ages ≥ 18 years.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.